Date Title  
Feb 06, 2019
Summary ToggleSol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%
 
Jan 15, 2019
Summary ToggleSol-Gel Technologies Appoints John Vieira as U.S. Head of Commercialization
 
Dec 17, 2018
Summary ToggleSol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
 
Dec 04, 2018
Summary ToggleSol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo
 
Nov 29, 2018
Summary ToggleSol-Gel Technologies Announces Participation in Upcoming Investor Conference
 
Nov 13, 2018
Summary ToggleSol-Gel Technologies Reports Third Quarter 2018 Financial Results
 
Nov 05, 2018
Summary ToggleSol-Gel Technologies Announces Participation in Upcoming Investor Conference
 
Nov 01, 2018
Summary ToggleSol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo
 
Sep 25, 2018
Summary ToggleSol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea
 
Sep 13, 2018
Summary ToggleSol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors
 
Displaying 31 - 40 of 52 results